Assessing Cochlear (ASX:COH) Valuation After Softer Half Year Results And Steady Interim Dividend

Simply Wall St.

Yesterday

Cochlear (ASX:COH) has drawn fresh attention after reporting half year 2025 earnings that showed lower sales and net income than a year earlier, while keeping its interim dividend and payout ratio ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614183780"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614183780\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614183780?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-02-26 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614183780","market":"nz","top_or_hot":-1,"title":"Assessing Cochlear (ASX:COH) Valuation After Softer Half Year Results And Steady Interim Dividend","media":"Simply Wall St.","content":"<div>\n<p>Cochlear (ASX:COH) has drawn fresh attention after reporting half year 2025 earnings that showed lower sales and net income than a year earlier, while keeping its interim dividend and payout ratio ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/assessing-cochlear-asxcoh-valuation-after-softer-half-year-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Cochlear (ASX:COH) Valuation After Softer Half Year Results And Steady Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Cochlear (ASX:COH) Valuation After Softer Half Year Results And Steady Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-26 13:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/assessing-cochlear-asxcoh-valuation-after-softer-half-year-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cochlear (ASX:COH) has drawn fresh attention after reporting half year 2025 earnings that showed lower sales and net income than a year earlier, while keeping its interim dividend and payout ratio ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/assessing-cochlear-asxcoh-valuation-after-softer-half-year-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/assessing-cochlear-asxcoh-valuation-after-softer-half-year-r","article_id":"2614183780","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/assessing-cochlear-asxcoh-valuation-after-softer-half-year-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614183780","pubTimestamp":1772083307,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cochlear (ASX:COH) has drawn fresh attention after reporting half year 2025 earnings that showed lower sales and net income than a year earlier, while keeping its interim dividend and payout ratio consistent.\nSee our latest analysis for Cochlear.\nAt around A$197.0 per share, Cochlear’s 1 day share price return of 2.07% sits against a 30 day share price decline of 28.03% and a 1 year total shareholder return decline of 24.66%, suggesting recent earnings and dividend news are being weighed...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK7007":"医疗保健设备","COH.AU":"COCHLEAR LTD"},"translate_title":"在半年业绩疲软和中期股息稳定后评估科利耳(ASX：COH)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"COH.AU":1.5},"content_text":"Cochlear (ASX:COH) has drawn fresh attention after reporting half year 2025 earnings that showed lower sales and net income than a year earlier, while keeping its interim dividend and payout ratio consistent. See our latest analysis for Cochlear. At around A$197.0 per share, Cochlear’s 1 day share price return of 2.07% sits against a 30 day share price decline of 28.03% and a 1 year total shareholder return decline of 24.66%, suggesting recent earnings and dividend news are being weighed against a softer longer term trend. If Cochlear’s recent move has you reassessing where growth and resilience might come from next, it could be worth scanning our screener of 10 healthcare AI stocks as potential ideas to research further. With earnings softer and the dividend steady, the share price slump has reshaped expectations. Is Cochlear now trading below what its fundamentals suggest, or is the market already factoring in its future growth potential? AdvertisementMost Popular Narrative: 21.4% Undervalued With Cochlear last closing at A$197.0 and the most followed narrative pointing to a fair value of A$250.59, the gap between price and thesis is clear and invites a closer look at what is driving that valuation work.  Ongoing investment in R&D, even in the face of cyclical sales weakness, supports continuous technological improvements (e.g., AI, diagnostics, upgradable firmware, smaller processors), enhancing product differentiation, sustaining premium pricing, and protecting gross margins for the long term.  Read the complete narrative. Want to see what kind of revenue and earnings path needs to sit behind that R&D story? And what profit multiple that would have to support? The answers are built into this narrative, along with a specific growth and margin glide path that has to play out for A$250.59 to make sense. Result: Fair Value of A$250.59 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, risks around pricing pressure in China and slower cochlear implant demand in key developed markets could challenge the case for a higher valuation. Find out about the key risks to this Cochlear narrative. Another View: Cash Flows Paint A Tighter Picture While the popular narrative suggests Cochlear could be 21.4% undervalued at a fair value of A$250.59, our DCF model comes out closer to A$180.21. At A$197, that implies the shares are trading above this cash flow view. This raises a simple question: which set of assumptions do you trust more, the story or the spreadsheet? Look into how the SWS DCF model arrives at its fair value. COH Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cochlear for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 6 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of optimism and caution leaves you on the fence, take a moment to review the underlying data for yourself and move quickly to form your own thesis. To see exactly what the market is excited about right now, it is worth checking out the 2 key rewards. Looking for more investment ideas? If Cochlear has sharpened your focus, do not stop here. The real edge often comes from lining up a few different high quality ideas to compare.  Spot potential bargains early by scanning our list of screener containing 12 high quality undiscovered gems that combine solid fundamentals with limited market attention. Strengthen your core holdings by checking companies in the solid balance sheet and fundamentals stocks screener (18 results) that prioritise financial resilience and cleaner balance sheets. Prioritise stability and income by reviewing 6 resilient stocks with low risk scores that score well on our risk checks and may help steady a volatile portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}